Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Intra-Cellular Therapies (ITCI)
NASDAQ:ITCI
RESEARCH TOOLSreports
Intra-Cellular Therapies (ITCI) Stock Price & Analysis
842 Followers
ITCI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$45.50 - $84.89
Previous Close$67.99
Volume1.40M
Average Volume (3M)1.31M
Market Cap
$7.18B
Enterprise Value$6.72B
Total Cash (Recent Filing)$475.62M
Total Debt (Recent Filing)$16.38M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Aug 06, 2024EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding105,574,855
10 Day Avg. Volume1,212,584
30 Day Avg. Volume1,308,128
Standard Deviation0.36
R-Squared0.02
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)13.67
Price to Sales (P/S)55.82
Price to Cash Flow (P/CF)-980.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue13.06
Enterprise Value/Gross Profit15.68
Enterprise Value/Ebitda-73.39
Forecast
1Y Price Target
$96.15Price Target Upside40.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Intra-Cellular Therapies News
Bulls Say, Bears Say
Bulls Say
EarningsCaplyta's launch in schizophrenia and bipolar depression continues to impress with sales on track to reach $2B at peak.
FDA ApprovalFDA approval for Caplyta in major depressive disorder seems very likely, given two robust Phase III datasets.
Market InterestTwo recent deals signal Big Pharma's renewed interest in CNS, creating a nice backdrop.
Bears Say
Market ExclusivityOngoing generic challenges to Caplyta could impact its market exclusivity and long-term profitability.
Market ExpectationHigh investor expectations based on Study 501 topline results have skewed the risk/reward to the downside.
Public OfferingThe company announced pricing of a public offering of 6,849,316 shares at a price of $73.00 per share.
---
Ownership Overview
31.90% Insiders
33.73% Mutual Funds
13.75% Other Institutional Investors
20.62% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ITCI FAQ
What was Intra-Cellular Therapies’s price range in the past 12 months?
Intra-Cellular Therapies lowest stock price was $45.50 and its highest was $84.89 in the past 12 months.
What is Intra-Cellular Therapies’s market cap?
Currently, no data Available
When is Intra-Cellular Therapies’s upcoming earnings report date?
Intra-Cellular Therapies’s upcoming earnings report date is Aug 06, 2024 which is in 34 days.
How were Intra-Cellular Therapies’s earnings last quarter?
Intra-Cellular Therapies released its earnings results on May 07, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.317 by $0.157.
Is Intra-Cellular Therapies overvalued?
According to Wall Street analysts Intra-Cellular Therapies’s price is currently Undervalued.
Does Intra-Cellular Therapies pay dividends?
Intra-Cellular Therapies does not currently pay dividends.
What is Intra-Cellular Therapies’s EPS estimate?
Intra-Cellular Therapies’s EPS estimate is -$0.19.
How many shares outstanding does Intra-Cellular Therapies have?
Intra-Cellular Therapies has 105,574,850 shares outstanding.
What happened to Intra-Cellular Therapies’s price movement after its last earnings report?
Intra-Cellular Therapies reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.317. Following the earnings report the stock price went up 0.282%.
Which hedge fund is a major shareholder of Intra-Cellular Therapies?
Among the largest hedge funds holding Intra-Cellular Therapies’s share is Perceptive Advisors LLC. It holds Intra-Cellular Therapies’s shares valued at 73M.
---
Intra-Cellular Therapies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$96.15 (40.28% Upside)
$96.15 (40.28% Upside)
Blogger Sentiment
Bullish
ITCI Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $337.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 24.8%
Last 30 Days ▲ 24.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.37%
12-Months-Change
Fundamentals
Return on Equity
-18.07%
Trailing 12-Months
Asset Growth
3.44%
Trailing 12-Months
Company Description
Intra-Cellular Therapies
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.
---
ITCI Earnings Call
Q1 2024
0:00 / 0:00
---
ITCI Stock 12 Month Forecast
Average Price Target
$96.15
▲(40.28% Upside)
Technical Analysis
Best Analysts Covering ITCI
1 Year
1 Year Success Rate
39/47 ratings generated profit
1 Year Average Return
+34.54%
reiterated a buy rating 8 days ago
Copying Brian Abrahams's trades and holding each position for 1 Year would result in 82.98% of your transactions generating a profit, with an average return of +34.54% per trade.
---